APVO

Aptevo Therapeutics Inc

• NASDAQ·09/04 14:09

  Weekly Buzz: IONS, MIST, BIIB, AZN Win Nods; TCRX, NVS Cut Jobs; OVID, VIR Data; REGN, PASG Deals

• TipRanks·09/03 15:50

  Aptevo AML data ‘highly encouraging,’ says Roth Capital

• NASDAQ·09/03 13:59

  Aptevo Reports 93% Clinical Benefit With Mipletamig Triplet In TP53-Mutated AML; Stock Down 17%

• TipRanks·09/03 12:48

  Aptevo Reports Promising Mipletamig Data in TP53-Mutant AML

• TipRanks·09/03 12:15

  Aptevo Therapeutics’ mipletamig triplet shows 93% benefit in leukemia

• TipRanks·08/21 20:36

  Aptevo Shareholders Back Board, Auditor and Incentive Plan

• TipRanks·08/21 20:15

  Aptevo Therapeutics files to sell 6.44M shares of common stock for holders

• TipRanks·08/18 08:10

  Analysts Offer Insights on Healthcare Companies: Aptevo Therapeutics (APVO) and Jasper Therapeutics (JSPR)

• TipRanks·08/16 13:30

  Aptevo Therapeutics reports $9.8M in cash, cash equivalents as of June 30

• TipRanks·08/13 21:20

  Aptevo Therapeutics Raises Capital Through Warrant-Induced Financing

• TipRanks·07/27 20:37

  Aptevo Therapeutics Unveils New Solid Tumor Strategy

• TipRanks·07/27 12:20

  Aptevo files patent application for Nectin-4 x PD-L1 dual-targeting backbone

• TipRanks·06/30 20:35

  Aptevo Therapeutics Secures Grant for APVO451 Development

• TipRanks·06/30 12:21

  Aptevo Therapeutics awarded $1.5M research grant from Andy Hill CARE Fund

• TipRanks·05/28 12:44

  Aptevo Therapeutics appoints Janatpour as SVP, CSO